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COPD: Are we using all the tools
we  have?
COPD  is  the  most  common  chronic  respiratory  disease
and  represents  today  the  4th  cause  of  death  worldwide;
it  has  an  estimated  prevalence  of  14.2%  in  Lisbon  adult
(over  40  years)  population.1 The  high  mortality  of  COPD
is  mainly  due  to  exacerbations  requiring  hospitalization,
and  in  patients  with  hypercapnia  and  respiratory  acidosis,
the  mortality  reaches  10%,  increasing  to  40%  in  the  ﬁrst
year  after  hospital  discharge.  The  goals  of  the  treatment
are  symptomatic  improvement,  and  preventing  disease
progression  and  exacerbations.
Dyspnoea  is  the  main  symptom  of  the  disease,  there
after  hospitalization.  In  fact,  pulmonary  rehabilitation  
regarded  as  one  of  the  most  effective  non-pharmacologic
treatments.8 However,  according  to  GOLD  guideline
physical  activity  is  recommended  for  all  patients  wit
COPD  only  because  it  seems  intuitively  correct,  but  withou
COPD-speciﬁc  evidence  to  support  any  recommendation
The  2015  CHEST  and  CTS  Guideline,9 a  document  ful
describing  the  current  state  of  knowledge  regarding  th
prevention  of  acute  exacerbation  of  COPD,  like  many  othe
papers,  do  not  include  any  recommendations  regardin
physical  activity  in  COPD.  So,  for  therapeutic  success  w
also  need  evidence  concerning  the  importance  of  regula
physical  activity  in  all  stages  of  COPD,  outside  the  con
text  of  pulmonary  rehabilitation,  and  how  to  get  patieni-
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adherence,  which  can  a  difﬁcult  task.
Thus,  in  the  absence  of  robust  knowledge  that  would
allow  us  to  predict  exacerbations,  the  main  cause  of  mortal-
ity  of  COPD,  using  these  tools  gives  the  physician  guidance
about  correct  treatment  according  to  the  best  medical  evi-
dence,  and  can  improves  adherence,  aid  device  selection
and  correct  inhalation  technique.
Conﬂicts of  interest
J,
s-
v
se
/
e
s.
R,
fs
d
,
y-
d
-
D.
ry
ns
v.
D,
D:
i-are  several  possible  measuring  instruments  but  the  Med
cal  Research  Council  Dyspnoea  Questionnaire  (mMRC)  wit
cross-cultural  adaptation  to  the  Portuguese  population  is  th
one  usually  recommended  because  of  its  sensitivity  and  eas
of  registration.  As  COPD  is  a  chronic,  progressive  and  mult
system  disease,  it  is  also  important  to  understand  its  impa
on  patient  quality  of  life  and  well-being,  and  so  the  CA
(COPD  Assessment  Test)  was  designed  to  measure  these,  an
its  use  is  recommended  by  international  guidelines.2 Thes
tools  cannot  be  ignored  in  daily  clinical  practice.
Adherence  to  treatment,  and  its  improvement,  is  a  cri
ical  issue  in  the  treatment  of  patients  with  COPD.  In  th
absence  of  a  ‘‘best  way’’  to  measure  adherence,  subjectiv
or  self-reported  methods,  such  as  those  exempliﬁed  by  th
MAT  --  Measurement  of  Treatment  Adherence,  validated  fo
the  Portuguese  population  in  2001,3 should  be  more  wide
used.  MAT  is  a  psychometric  measure  which  is  easy  to  use  
clinical  practice  providing  good  sensitivity  and  speciﬁcity.
Despite  the  importance  of  knowing  about  adherence
some  psychometric  measures  say  little  or  nothing  abou
the  reasons  for  non-adherence.  An  instrument  of  evalu
ation  of  the  beliefs  about  medicines,  Escala  de  Crenc¸a
Acerca  de  Medicamentos,  cross-cultural  adaptation  of  th
BMQ-Speciﬁc  (Beliefs  About  Medicines  Questionnaire)4 int
Portuguese  for  the  general  population  of  medicine  user
can  help  discover  practical  barriers  to  adherence  to  inhale
therapy.  The  BMQ,  an  eleven-item  questionnaire  with  
ﬁve-item  Necessity  scale  and  a  six-item  Concerns  scale
essentially  studies  intentional  non-adherence,  and  it  is  eas
to  use  in  clinical  practice.
Therapeutic  success  is  also  dependent  on  a  good  inhale
technique,  it  has  been  demonstrated  by  meta-analys
that  when  the  patient  uses  them  correctly,  the  variou
inhaler  devices  have  similar  therapeutic  effects.5 We  nee
to  demonstrate  at  all  medical  visits  how  to  use  the  inhale
devices  correctly,  but  we  have  also  to  check  how  th
patient  uses  it.  Checklists6 with  the  number  of  steps  for  th
correct  use  of  devices,  including  a  critical  step  which  if  no
performed  would  result  in  no  drug  delivery,  can  be  usef
in  clinical  practice.  The  choice  of  the  inhaler  device  is  s
important  that  some  authors  propose  a  single  algorithm  or
checklist  to  guide  selection7 in  primary  care  practice.
The  role  of  pulmonary  rehabilitation  in  COPD  has  been
carefully  evaluated,  with  some  beneﬁts  showing  an  A  level
of  evidence.  Pulmonary  rehabilitation  improves  exercise
capacity  and  health-related  quality  of  life,  reduces  the  exa-
cerbations  requiring  hospitalizations  and  improves  recoveryThe  author  has  no  conﬂicts  of  interest  to  declare.
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